STXS
ANALYST COVERAGE10 analysts
BUY
+96.6%upside to target
Buy
10100%
10 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
PRICE
Prev Close
1.85
Open
1.87
Day Range1.76 – 1.89
1.76
1.89
52W Range1.74 – 3.59
1.74
3.59
2% of range
VOLUME & SIZE
Avg Volume
417.3K
FUNDAMENTALS
P/E Ratio
-7.4x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.43
Market-like
TECHNICAL
RSI (14)
52
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 20
DEx-Dividend
In 90 days
Aug 17
PDividend Pay
In 97 days
Aug 24
Key MetricsTTM
Market Cap$173.97M
Revenue TTM$31.20M
Net Income TTM-$21.68M
Free Cash Flow-$15.52M
Gross Margin53.9%
Operating Margin-68.5%
Net Margin-69.5%
Return on Equity-153.2%
Return on Assets-40.1%
Debt / Equity0.27
Current Ratio1.55
EPS TTM$-0.22

STXS News

About

stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. these innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. over 100 issued patents support the stereotaxis platform. the core components of stereotaxis’ systems have received regulatory clearance in the united states, european union, japan, canada, china, and elsewhere. for more information, please visit www.stereotaxis.com.

Industry
Surgical and Medical Instrument Manufacturing
CEO
David Fischel
David Leo FischelChief Executive Officer & Chairman
Keith GallowayVice President of Operations
Kimberly R. PeeryChief Financial Officer
Patricia S. WilliamsGeneral Counsel & Secretary